Merck to Acquire Alydia Health for ~$240M on Behalf of its Planned Spinoff of Organon

 Merck to Acquire Alydia Health for ~$240M on Behalf of its Planned Spinoff of Organon

Merck to Acquire Alydia Health for ~$240M on Behalf of its Planned Spinoff of Organon

Shots:

  • Organon to acquire Alydia Health for up to $240M including $215M up front out of which $50 will be paid prior to the spinoff of Organon, $165 will be paid on the closure of the acquisition while remaining will be paid upon achievement of the milestones. Alydia will also receive ~$25M as a contingent milestone
  • The acquisition is expected to close after the completion of the spinoff of Organon from Merck, expected in Q2’21
  • The acquisition will foster the delivery of the Jada System to prevent maternal morbidity and mortality caused by PPH or abnormal postpartum uterine bleeding

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post